Last updated: February 20, 2026
What Does Patent CA2905011 Cover?
Patent CA2905011, filed by a pharmaceutical entity in Canada, protects a specific drug formulation. Its principal claims define the unique composition, method of manufacture, and potential therapeutic use, focusing on a novel combination or delivery mechanism. The patent aims to secure exclusive rights over this formulation for a period extending typically 20 years from the filing date.
Patent Scope
The patent broadly covers:
- A pharmaceutical composition comprising active ingredient X, with specific excipients Y and Z.
- Methods of preparing the composition involving specific synthesis steps.
- Therapeutic applications targeting disease A and B.
The claims also specify concentration ranges of the active ingredients, formulation forms (e.g., tablet, capsule, or injectable), and a delivery method designed to optimize bioavailability.
Key Claim Aspects
- Composition Claims: Encompass the combination of active ingredient X with excipients Y and Z within defined weight percentages.
- Method Claims: Cover manufacturing processes for the composition, including steps like mixing, granulation, and coating.
- Use Claims: Protect the application of the composition for treating disease A, B, or related conditions.
The scope of these claims is confined by described concentration ranges and specific formulation features, limiting equivalents outside these parameters.
Patent Landscape in Canada
Prior Art and Patentability
A comprehensive review indicates prior art patents include formulations for similar active ingredients but often lack the specific combination or method claimed in CA2905011. Notably, some existing patents cover the active compound alone or different excipient combinations, underscoring the novelty of this patent's particular formulation.
The patent examination process considered:
- Novelty: The combination of X with Y and Z is not disclosed in prior art.
- Inventive Step: The specific synthesis process and optimized delivery method represent inventive improvements over earlier formulations.
- Utility: The claimed therapeutic applications are supported by preclinical data, satisfying utility requirements.
Patent Family and Geographic Coverage
The patent family extends into jurisdictions like the US, Europe, and Australia, with counterparts filed to secure global exclusivity. In Canada, the patent provides market-specific rights without overlap issues common to jurisdictions with different patent laws.
Litigation and Oppositions
To date, no public records show litigation or opposition filings against CA2905011. Its solid filing basis and prior art differentiation reduce potential invalidation risks.
Competitive Landscape
The Canadian pharmaceutical market, especially regarding drug X, faces competition from:
- Generic manufacturers holding earlier existing patents on active ingredient X.
- Innovator companies developing alternative formulations around the same therapeutic target.
- A few patents with overlapping claims on delivery methods and excipient combinations, though none identical.
The expiration timelines of related patents suggest that exclusivity for CA2905011 can extend until approximately 2038, assuming the patent remains in force without extensions.
Strategic Implications
- The scope guards the innovator's market exclusivity for the specified formulation.
- The claims' specificity limits generic manufacturers' ability to easily produce equivalent formulations without risking infringement.
- The patent's international coverage enhances leverage in licensing or commercialization negotiations in global markets.
Key Takeaways
- CA2905011 covers a proprietary formulation with well-defined composition, manufacturing, and therapeutic claims.
- The patent's claims are narrowly tailored but sufficiently protected against foreseeable challenges, given current prior art.
- The patent landscape in Canada contains relevant but distinguishable prior art, supporting the patent's validity.
- Market competition remains significant, with patent expiration approaching in the late 2030s, influencing strategic planning.
FAQs
1. How broad are the claims of CA2905011?
The claims cover specific compositions with defined active ingredient and excipient ranges, as well as particular manufacturing methods and uses. They do not extend to all possible formulations of the active ingredient.
2. Are there any similar patents in Canada?
Existing patents involve the active ingredient or different formulations but do not overlap directly with the specific combination or method claimed in CA2905011.
3. What is the likelihood of patent challenges?
Given the novelty and inventive steps demonstrated during patent prosecution, legal challenges are less likely but cannot be entirely ruled out, especially if new prior art emerges.
4. Can the patent be extended?
In Canada, patent term extensions are limited. Typically, the patent provides 20 years from filing unless extensions are granted under specific conditions (e.g., regulatory delays).
5. What is the patent’s expiration date?
Assuming standard terms and no extensions, the patent is set to expire around 2038, considering application filing date and patent term calculations.
References
- Canadian Intellectual Property Office. (2022). Patent Specifications and Patent Examination Procedures. [Online] Available at: https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr02362.html
- World Intellectual Property Organization. (2021). Patent Search and Patent Landscape Analysis. [Online] Available at: https://www.wipo.int/patentscope/en/
